2W60 logo

Mustang Bio DB:2W60 Stock Report

Last Price

€4.84

Market Cap

€46.2m

7D

0%

1Y

-40.6%

Updated

01 Jul, 2023

Data

Company Financials +

2W60 Stock Overview

A clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.

2W60 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Mustang Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mustang Bio
Historical stock prices
Current Share PriceUS$4.84
52 Week HighUS$11.06
52 Week LowUS$4.19
Beta1.85
11 Month Change0%
3 Month Change-3.53%
1 Year Change-40.63%
33 Year Changen/a
5 Year Changen/a
Change since IPO-88.23%

Recent News & Updates

Recent updates

Shareholder Returns

2W60DE BiotechsDE Market
7D0%0.5%-1.4%
1Y-40.6%-16.2%11.8%

Return vs Industry: 2W60 underperformed the German Biotechs industry which returned -23.1% over the past year.

Return vs Market: 2W60 underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 2W60's price volatile compared to industry and market?
2W60 volatility
2W60 Average Weekly Movementn/a
Biotechs Industry Average Movement5.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2W60 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 2W60's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015113Manny Litchmanwww.mustangbio.com

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.

Mustang Bio, Inc. Fundamentals Summary

How do Mustang Bio's earnings and revenue compare to its market cap?
2W60 fundamental statistics
Market cap€46.25m
Earnings (TTM)-€68.20m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2W60 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$74.42m
Earnings-US$74.42m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-9.16
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio92.5%

How did 2W60 perform over the long term?

See historical performance and comparison